0001437749-17-015577.txt : 20170905
0001437749-17-015577.hdr.sgml : 20170904
20170905163002
ACCESSION NUMBER: 0001437749-17-015577
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170901
FILED AS OF DATE: 20170905
DATE AS OF CHANGE: 20170905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SANDBERG RICHARD A
CENTRAL INDEX KEY: 0001245055
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36200
FILM NUMBER: 171069057
MAIL ADDRESS:
STREET 1: 330 NEVEDA STREET
CITY: NEWTON
STATE: MA
ZIP: 02460-1458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oxford Immunotec Global PLC
CENTRAL INDEX KEY: 0001586049
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
BUSINESS PHONE: 44 01235 442780
MAIL ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
4
1
rdgdoc.xml
FORM 4
X0306
4
2017-09-01
0001586049
Oxford Immunotec Global PLC
OXFD
0001245055
SANDBERG RICHARD A
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE
X0
OX14 4RZ
UNITED KINGDOM
1
Ordinary Shares
2017-09-01
4
M
0
3000
0.81
A
18000
D
Ordinary Shares
2017-09-01
4
S
0
3000
15.8199
D
15000
D
Stock Option (Right to Buy)
0.81
2017-09-01
4
M
0
3000
0
D
2022-12-31
Ordinary Shares
3000
2778
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017.
The price reported for the sales on September 1, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.7601 to $15.9000 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016.
/s/ Elizabeth M. Keiley, as Attorney-in-Fact for Richard A. Sandberg
2017-09-05